Patient-reported outcome measures in drugs for neurological conditions approved by European Medicines Agency 2017–2022

BACKGROUND: Regulatory agencies have been responsive to public demand for inclusion of the patient experience in evaluating and approving therapies. Over the years, patient-reported outcome measures (PROMs) have become increasingly prevalent in clinical trial protocols; however, their influence on r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciani, Oriana, Meregaglia, Michela, Battaglia, Mario Alberto, Brichetto, Gianpaolo, Conte, Antonella, Gasperini, Claudio, Sansone, Valeria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Brief Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344960/
https://www.ncbi.nlm.nih.gov/pubmed/37145229
http://dx.doi.org/10.1007/s10072-023-06825-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10344960/
https://www.ncbi.nlm.nih.gov/pubmed/37145229
http://dx.doi.org/10.1007/s10072-023-06825-6

Ejemplares similares